April 18, 2023
Otsuka Pharmaceutical/Lundbeck’s atypical antipsychotic Rexulti (brexpiprazole) has bagged the nod of FDA advisors, inching closer to US approval for its label expansion that would make it the country’s first medicine to treat agitation associated with Alzheimer’s dementia (AAD). The two...read more